Trigen

Trigen is a South Korean biotechnology company specializing in the development of next-generation multi-specific antibody therapeutics for oncology. The company's core technology is the proprietary T-GEn platform, which enables the engineering of tri-specific antibodies capable of simultaneously binding to three different antigens. This approach is designed to enhance therapeutic efficacy and overcome resistance mechanisms in complex cancers while improving safety profiles, particularly for challenging targets like CD47. Trigen's lead candidate, TG-001, is a tri-specific antibody targeting CD47, PD-L1, and a tumor-associated antigen, currently in pre-clinical development for solid tumors. The company aims to leverage its antibody engineering expertise to address significant unmet needs in immuno-oncology.